Dyne Therapeutics, Inc.
NNASDAQ:DYNCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John G. Cox
- Full Time Employees
- 258
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 1560 Trapelo Road Waltham MA United States 02451
- IPO Date
- Sep 17, 2020
- CIK
- 0001818794
- Website
- dyne-tx.com
- Similar Companies
- Business
- Dyne Therapeutics, Inc. Dyne Therapeutics, Inc. (NASDAQ: DYN) is a clinical-stage biotechnology company focused on developing nucleic acid therapeutics for genetically driven neuromuscular diseases using its proprietary FORCE platform, which enables targeted delivery of oligonucleotides to muscle and the central nervous system. Founded in 2017 and headquartered in Waltham, Massachusetts, the company advances a broad pipeline including lead clinical candidates z-basivarsen, an antisense oligonucleotide (ASO) conjugated to a transferrin receptor 1-binding Fab for myotonic dystrophy type 1 (DM1) via the Phase 1/2 ACHIEVE trial targeting toxic DMPK RNA reduction; z-rostudirsen, a phosphorodiamidate morpholino oligomer (PMO) conjugated to a TfR1-binding Fab for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping via the Phase 1/2 DELIVER trial aiming to restore dystrophin production; preclinical programs such as DYNE-302, an siRNA conjugate for facioscapulohumeral muscular dystrophy (FSHD) suppressing DUX4 expression; additional DMD candidates targeting exons 53, 45, and 44; and efforts in Pompe disease, with global operations pursuing regulatory designations across the U.S., EU, and Japan. Core offerings emphasize muscle-targeted therapies addressing root causes like spliceopathy in DM1 affecting approximately 40,000 U.S. patients, dystrophin loss in DMD impacting 12,000 U.S. individuals, and DUX4 toxicity in FSHD; z-basivarsen and z-rostudirsen have secured FDA Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric designations, alongside EMA and Japanese approvals. Recent developments include FDA Breakthrough Therapy Designation for DYNE-101 (z-basivarsen) in DM1 in June 2025 and for DYNE-251 (z-rostudirsen) in DMD in August 2025; full enrollment of registrational expansion cohorts in ACHIEVE and DELIVER trials with data expected mid-2026 and late 2025 to support potential U.S. accelerated approval submissions in 2026; closure of a $230 million public stock offering in July 2025 extending cash runway into Q3 2027; plans for confirmatory Phase 3 DM1 trial initiation in Q1 2026; leadership team enhancements in early 2025 ahead of anticipated 2027 commercial launches; and ongoing preclinical expansion in DMD exons and Pompe disease.
Company News
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Stock Traders Buy High Volume of Dyne Therapeutics Call Options (NASDAQ:DYN)
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Dyne Therapeutics, Inc. $DYN is Atlas Venture Life Science Advisors LLC’s 2nd Largest Position
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
Dyne Therapeutics to Participate in Upcoming Investor Conferences
ADAR1 Capital Management LLC Buys Shares of 42,821 Dyne Therapeutics, Inc. $DYN
242,392 Shares in Dyne Therapeutics, Inc. $DYN Acquired by Deutsche Bank AG
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fifth Third Bancorp Buys New Shares in Dyne Therapeutics, Inc. $DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock